Jasper Therapeutics (JSPR) Share-based Compensation (2020 - 2026)

Jasper Therapeutics has reported Share-based Compensation for 7 years, with the latest figure at $4.4 million in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 142.16% year-over-year to $4.4 million in Q2 2026; TTM through Jun 2026 was $4.4 million, a 36.73% decrease from a year earlier, with the FY2025 full-year figure at $8.9 million, down 37.76% from the prior year.
• Share-based Compensation was $4.4 million for Q2 2026 at Jasper Therapeutics, up from $1.7 million in the prior quarter.
• The five-year high for Share-based Compensation was $15.0 million in Q1 2025, with the low at $1.2 million in Q4 2023.
• Average Share-based Compensation over 5 years is $3.3 million, with a median of $1.8 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation jumped 1941.75% in 2022, then slumped 78.48% in 2023.
• Over 5 years, Share-based Compensation stood at $1.6 million in 2022, then slipped by 27.81% to $1.2 million in 2023, then jumped by 70.12% to $2.0 million in 2024, then retreated by 15.69% to $1.7 million in 2025, then surged by 164.9% to $4.4 million in 2026.
• The last three Share-based Compensation figures came in at $4.4 million (Q2 2026), $1.7 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.